Linezolid is a powerful antibiotic, but it must be used as a last resort.
In short: Linezolid is a unique, synthetic antibiotic that stops bacteria by blocking protein production at the initiation stage. While it is highly effective against dangerous, drug-resistant pathogens like MRSA, its potential for serious long-term side effects means it is strictly reserved for cases where other, safer treatments have failed.
Discovered in the mid-1990s and approved for use in 2000, linezolid belongs to the oxazolidinone class of medications. It is a vital tool against Gram-positive bacteria, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Unlike many antibiotics that kill bacteria by interfering with later stages of protein synthesis, linezolid acts uniquely by binding to the 23S portion of the 50S ribosomal subunit. This prevents the formation of the initiation complex, effectively halting bacterial growth. Because of this distinct mechanism, cross-resistance with other protein synthesis inhibitors remains rare.
A major advantage of linezolid is its 100% oral bioavailability, allowing patients to switch from intravenous to oral therapy seamlessly. It also penetrates tissues well, including the epithelial lining fluid of the lungs, which supports its use in pneumonia. However, it is classified as a reserve antibiotic. Because it is a weak, non-selective monoamine oxidase inhibitor, it can trigger dangerous serotonin syndrome if combined with certain antidepressants or tyramine-rich foods. Furthermore, long-term use—typically defined as exceeding two weeks—carries risks of bone marrow suppression, peripheral neuropathy, and optic nerve damage, which may be irreversible.
While linezolid is highly effective, resistance is emerging. Recent studies have identified specific resistance genes, such as cfr and optrA, as well as mutations in the 23S rRNA gene, including a novel C2626T mutation found in Indian clinical isolates. These findings highlight the necessity of molecular surveillance. Because of these risks and the potential for resistance, clinical guidelines emphasize using linezolid sparingly. It is not a first-line treatment for most infections; rather, it is a critical, last-resort option that requires careful monitoring of blood counts and neurological health when extended therapy is unavoidable.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Linezolid
- Also: Molecular Detection of Linezolid Resistance Determinants and Identification of a Novel C2626T Mutation in Clinical Isolates of <i>Enterococcus</i> Species from India.
To cite this card, link to https://intellectplus.co.uk/app/health-linezolid.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics
